In this edition:
DESTINYBreast-12: T-DXd in HER2+ breast cancer with brain metastases
KEYNOTE-522: final OS results
HypoG-01: hypofractionated loco-regional radiotherapy in early breast cancer
NATALEE: updated 4-year data
OptiTrain: high-intensity exercise & breast cancer outcomes
ICARUS-BREAST01: HER3-DXd in HR+/HER2- advanced breast cancer
Triple-B: first-line carboplatin-cyclophosphamide vs. paclitaxel ± atezolizumab in metastatic TNBC
Updated HER2 status assessments in HR+ metastatic breast cancer in DESTINY-Breast06
IBI354 (anti-HER2 ADC) in advanced breast cancer
I-SPY 2.2: neoadjuvant regimens based on ‘response predictive subtypes’
Please login below to download this issue (PDF)